Search Results
Oct 24, 2025, 04:00 ET Renalys Pharma to be Acquired by Chugai Pharmaceutical
glomerulosclerosis (FSGS) and Alport syndrome in Japan. Renalys believes that transferring sparsentan to Chugai, a company recognized for its rare-disease and nephrology expertise, will accelerate access for patients across Asia. BT Slingsby, MD, PhD, MPH, Representative
More news about: Renalys Pharma, Inc.
Oct 23, 2025, 23:24 ET La FDA accorde la désignation Fast Track à AJ201, une thérapie inédite pour la maladie de Kenndy
À propos de la SBMA et de l'AJ201 La SBMA, ou maladie de Kennedy, est une maladie neuromusculaire rare, héréditaire et liée au chromosome X, causée par l'expansion de la répétition CAG dans le gène du récepteur des androgènes (AR). La protéine AR mutante
More news about: AnnJi Pharmaceutical Co., Ltd.
Oct 23, 2025, 21:54 ET Bybit x Block Scholes September Volatility Report: Volatility Awakens with the First Term Structure Inversion in Months
developments — specifically, the re-escalation of trade hostilities between the United States and China. Following Beijing's new export controls on rare earth minerals, U.S. President Donald Trump announced plans for a 100% tariff on Chinese imports. The announcement made after traditional markets had
More news about: Bybit
Oct 23, 2025, 21:41 ET Bybit x Block Scholes September Volatility Report: Volatility Awakens with the First Term Structure Inversion in Months
developments — specifically, the re-escalation of trade hostilities between the United States and China. Following Beijing's new export controls on rare earth minerals, U.S. President Donald Trump announced plans for a 100% tariff on Chinese imports. The announcement made after traditional markets had
More news about: Bybit
Oct 23, 2025, 18:54 ET Defense Metals Appoints Ali Mahdavi as SVP Corporate Development, and grants incentive stock options
unparalleled depth of experience throughout the entire rare earth element value chain and will be a key addition for Defense Metals as we move forward." "I am thrilled to join Defense at a point in time when Critical Minerals and Rare Earth Element projects are taking centre stage on
More news about: Defense Metals Corp.
Oct 23, 2025, 16:05 ET Insmed Ranks No. 1 on Science's 2025 Top Biopharma Employers List
series of clinical successes and regulatory milestones that support us in working toward our mission to transform the lives of patients with serious and rare diseases. This recognition reflects not only our deep commitment to advancing science, but also the passion and purpose that drive our work every day."
More news about: Insmed Incorporated
Oct 23, 2025, 16:05 ET Inhibrx Biosciences Reports Positive Topline Results from its Registrational Trial of Ozekibart (INBRX-109) in Chondrosarcoma and Provides Updates on Colorectal Cancer and Ewing Sarcoma Expansion Cohorts
Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for oncology and rare diseases, today announced positive topline results from the registrational ChonDRAgon study (n= 206) investigating ozekibart (INBRX-109) as a single
More news about: Inhibrx Biosciences, Inc.
Oct 23, 2025, 15:50 ET Wines of Friuli Venezia Giulia Debut in New York City with Resounding Success
categories and help determine the industry leaders. Agency principals have years of experience in retail and distribution as well as communications, a rare combination that gives Colangelo & Partners invaluable insights into consumer purchasing behavior. The agency focuses on "closing the loop" between
More news about: UNI.DOC FVG
Oct 23, 2025, 14:36 ET Zenocutuzumab-zbco Granted FDA Breakthrough Therapy Designation for NRG1+ Cholangiocarcinoma; Data Highlighting Potential of Zenocutuzumab-zbco in NRG1+ Cholangiocarcinoma to be Presented at AACR-NCI-EORTC
and eligibility for rolling review and priority review. For adult patients with advanced unresectable or metastatic NRG1+ cholangiocarcinoma, a rare and aggressive cancer with limited treatment options, this designation underscores the urgent need for effective therapies and recognizes the potential
More news about: Partner Therapeutics, Inc.
Oct 23, 2025, 14:01 ET Waterford Returns as the Official Crystal of the Times Square New Year's Eve Ball & One Times Square Reveals Early Look at New Ball Design
captures the spirit of this iconic celebration." This fall, in connection with the new One Times Square, visitors will have the rare opportunity to see the 2025 New Year's Eve Ball up close and participate in the evolution of its transition into the 2026 Ball design, taking part in
More news about: One Times Square; Waterford
Oct 23, 2025, 12:08 ET Hardin's Creek® Kentucky Straight Bourbon Whiskey Unveils the Warehouse Series: A Three-Part Exploration of Flavor and Discovery
is a three-part collection consisting of Warehouse R ("Mushroom"), Warehouse W ("Beaver") and Warehouse G ("Owl") releases. The collectible, rare series highlights how changes to an aging environment during maturation – the warehouse itself - profoundly shapes the whiskey.
More news about: Suntory Global Spirits
Oct 23, 2025, 12:00 ET A New Book About the History of the Postal Service is Now for Sale
deliver to Americans the words that help them understand themselves, each other, and their place in the world. The book includes rare photographs, documents and artifacts. It showcases postal uniforms, hand stamps, pneumatic mail systems and Post Office-themed music. The book delves
More news about: U.S. Postal Service
Oct 23, 2025, 10:19 ET Oakley Spirits Unveils Signature Blend Kentucky Straight Bourbon
highly anticipated launch of Signature Blend Kentucky Straight Bourbon, a bold new expression that follows the astonishing one-day sell-out of its rare Collector's Edition I Twenty Year Kentucky Straight Bourbon. This latest offering builds on that remarkable momentum and reflects the immense
More news about: Oakley Spirits
Oct 23, 2025, 10:00 ET INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Protalix BioTherapeutics, Inc. - PLX
information about joining the class action] On October 17, 2025, Protalix and Chiesi Global Rare Diseases, Protalix's partner in "the development, production and commercialization of recombinant therapeutic proteins produced by its proprietary ProCellEx®
More news about: Pomerantz LLP
Oct 23, 2025, 10:00 ET Pomerantz Law Firm Announces the Filing of a Class Action Against Savara Inc. and Certain Officers - SVRA
the class action] Savara is a clinical-stage biopharmaceutical company focused on rare respiratory diseases. The Company's lead product candidate is MOLBREEVI (also referred to as "molgramostim"), an inhaled granulocyte-macrophage colony-stimulating
More news about: Pomerantz LLP
Oct 23, 2025, 10:00 ET Hilco Global Announces the hiring of David H. Crawford to Expand the Higher Education and Faith-Based Organization Real Estate Advisory Practice
buildings in North America, and practiced law in the Bankruptcy and Restructuring Group at Kirkland & Ellis. "David brings a rare combination of strategic insight, operational excellence, and deep relationship capital across sectors that are central to Hilco's mission to grow,"
More news about: Hilco Global
Oct 23, 2025, 09:00 ET Matterhorn Venture Partners Expands Chicago Portfolio with Infill Franklin Park Small-Bay Acquisition
appeal, and prepare the units for immediate lease-up. "Small-bay industrial assets like Franklin Park are becoming increasingly rare, particularly in core infill markets," said Tina Ramos, Principal and Co-Founder of Matterhorn Venture Partners. "By acquiring this property well below
More news about: Matterhorn Venture Partners LLC
Oct 23, 2025, 09:00 ET ABERFELDY© SINGLE MALT SCOTCH WHISKY DEBUTS 15 YEAR OLD BOLGHERI RED WINE CASK FINISH AS THE LATEST EDITION TO ITS ILLUSTRIOUS WINE CASKS SERIES
Master Stephanie Macleod and her team, the whisky was first matured in refill and hogshead casks for 15 years before being finished for two years in rare Tuscan Bolgheri casks. This careful process has allowed the red wine cask to complement ABERFELDY's already exquisite character, adding an extra dimension
More news about: ABERFELDY Single Malt Scotch Whisky
Oct 23, 2025, 08:49 ET FBS: The Market Learns to Move Without the Fed
FBS analysts, this rare information blackout hasn't removed liquidity, it has only made it invisible. The global M2 liquidity index remains elevated across the US, Europe,
More news about: FBS
Oct 23, 2025, 08:39 ET Helmsman Imports Marks, A New York-based Strategic Partner to Premium and Craft Beverage Brands Seeking to Launch and Grow in the U.S. Market, Announces 100 Brand Milestone, Empowering Innovation in the U.S. Market
Rare Character Whiskey — Rare Character Whiskey stands apart as a curator of exceptional American whiskeys. Leveraging deep partnerships with top distillers, the brand sources distinctive, limited expressions that have never been available to the public. Each selection reflects Rare Character's
More news about: Helmsman Imports
Oct 23, 2025, 08:37 ET Cannabis Powerhouse Dime Industries Debuts in New Jersey With Ice-T Launch Event at The Medicine Woman Jersey City
Peach Ice-T All In One Dime Industries collaboration vape, available exclusively at The Medicine Woman Jersey City. Fans will have the rare opportunity to meet Ice-T in person and receive signed autographs during the launch. The Peach Ice-T vape will buy one get one free for the first
More news about: Dime Industries
Oct 23, 2025, 08:30 ET A1R WATER and Southern Glazer's Wine & Spirits National Distribution Agreement
$2.0B space exploration company Intuitive Machines, Inc. In March 2025, Inflection Point II combined with the $1.4B vertically integrated rare earth magnet company USA Rare Earth, Inc. The keystone in Inflection Point's strategy and continued success is leading committed-capital investments into their business
More news about: Air Water Ventures Holdings Ltd.
Oct 23, 2025, 08:30 ET Drug Compendia: Practical Strategies to Bridge Evidence and Payer Coverage, Upcoming Webinar Hosted by Xtalks
provider and payer frameworks. The speakers will share how a proactive compendia strategy can accelerate patient access, especially for therapies targeting rare or high-unmet-need populations. They will also explore the strategic value of submission timing to compendia, i.e., before or alongside a first indication,
More news about: Xtalks
Oct 23, 2025, 08:15 ET Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
The FDA grants Orphan Drug Designation to therapies intended for the treatment, prevention, or diagnosis of rare diseases or conditions that affect fewer than 200,000 people in the United States at the time of designation. "This designation
More news about: Halia Therapeutics
Oct 23, 2025, 08:15 ET Ofirnoflast (HT-6184) Receives Orphan Drug Designation from U.S. FDA for Myelodysplastic Syndromes
The FDA grants Orphan Drug Designation to therapies intended for the treatment, prevention, or diagnosis of rare diseases or conditions that affect fewer than 200,000 people in the United States at the time of designation. "This designation
More news about: Halia Therapeutics